152 related articles for article (PubMed ID: 18159051)
1. Investigational drug slows bone erosion.
Hampton T
JAMA; 2007 Dec; 298(24):2856. PubMed ID: 18159051
[No Abstract] [Full Text] [Related]
2. [Denosumab as the potent therapeutic agent against Paget's disease of bone].
Hirao M; Hashimoto J
Clin Calcium; 2011 Aug; 21(8):1231-8. PubMed ID: 21814030
[TBL] [Abstract][Full Text] [Related]
3. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
4. [Innovations in the treatment of osteoporosis].
Tsourdi E; Hofbauer LC
Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
[No Abstract] [Full Text] [Related]
5. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
Maldonado-Gonzales E; Pietschmann P
Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
[TBL] [Abstract][Full Text] [Related]
6. Denosumab an option for patients with bone metastasis from breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
[No Abstract] [Full Text] [Related]
7. Denosumab: new horizons in the treatment of osteoporosis.
Wilton JM
Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
[No Abstract] [Full Text] [Related]
8. [Advances treatment of osteoporosis: new molecules, new strategies].
Orcel P
Bull Acad Natl Med; 2010 Nov; 194(8):1505-16; discussion 1516-8. PubMed ID: 22046713
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
[No Abstract] [Full Text] [Related]
10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
11. Denosumab, osteoporosis, and prevention of fractures.
Blythe SL
N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
[No Abstract] [Full Text] [Related]
12. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
13. Denosumab: second chapter in controlling bone metastases or a new book?
Fornier MN
J Clin Oncol; 2010 Dec; 28(35):5127-31. PubMed ID: 21060038
[No Abstract] [Full Text] [Related]
14. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
Deodhar A; Dore RK; Mandel D; Schechtman J; Shergy W; Trapp R; Ory PA; Peterfy CG; Fuerst T; Wang H; Zhou L; Tsuji W; Newmark R
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):569-74. PubMed ID: 20391513
[TBL] [Abstract][Full Text] [Related]
15. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
Vignot S; Khayat D
J Clin Oncol; 2009 Apr; 27(10):1534-6. PubMed ID: 19237628
[No Abstract] [Full Text] [Related]
16. Molecule of the Month. Denosumab.
Drug News Perspect; 2009; 22(6):356. PubMed ID: 19771324
[No Abstract] [Full Text] [Related]
17. Denosumab, osteoporosis, and prevention of fractures.
Blackwood J
N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
[No Abstract] [Full Text] [Related]
18. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
19. The long and the short of bone therapy.
Whyte MP
N Engl J Med; 2006 Feb; 354(8):860-3. PubMed ID: 16495400
[No Abstract] [Full Text] [Related]
20. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.
West H
J Clin Oncol; 2011 Mar; 29(9):1095-8. PubMed ID: 21343550
[No Abstract] [Full Text] [Related]
[Next] [New Search]
